Translational insights and new therapeutic perspectives in head and neck tumors

Morena Fasano; Francesco Perri; Carminia Maria Della Corte; Raimondo Di Liello; Giuseppina Della Vittoria Scarpati; Marco Cascella; Alessandro Ottaiano; Fortunato Ciardiello; Raffaele Solla

doi:10.3390/biomedicines9081045

Translational insights and new therapeutic perspectives in head and neck tumors

Morena Fasano, Francesco Perri, Carminia Maria Della Corte, Raimondo Di Liello, Giuseppina Della Vittoria Scarpati, Marco Cascella, Alessandro Ottaiano, Fortunato Ciardiello, Raffaele Solla

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Review article › peer-review

Abstract

Head and neck squamous cell carcinoma (HNSCC) is characterized by a high mortality rate owing to very few available oncological treatments. For many years, a combination of platinum-based chemotherapy and anti-EGFR antibody cetuximab has represented the only available option for first-line therapy. Recently, immunotherapy has been presented an alternative for positive PD-L1 HNSCC. However, the oncologists’ community foresees that a new therapeutic era is approaching. In fact, no-chemo options and some molecular targets are on the horizon. This narrative review addresses past, present, and future therapeutic options for HNSCC from a translational point of view.

Original language	English
Article number	1045
Journal	Biomedicines
Volume	9
Issue number	8
DOIs	https://doi.org/10.3390/biomedicines9081045
Publication status	Published - Aug 2021

Keywords

DNA damage response
Epithelial growth factor receptor
Head and neck squamous cell carcinoma
Immunotherapy

ASJC Scopus subject areas

Medicine (miscellaneous)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.3390/biomedicines9081045

Cite this

@article{d47dd76c9ce74e48bcd0e0eddc4abf2c,

title = "Translational insights and new therapeutic perspectives in head and neck tumors",

abstract = "Head and neck squamous cell carcinoma (HNSCC) is characterized by a high mortality rate owing to very few available oncological treatments. For many years, a combination of platinum-based chemotherapy and anti-EGFR antibody cetuximab has represented the only available option for first-line therapy. Recently, immunotherapy has been presented an alternative for positive PD-L1 HNSCC. However, the oncologists{\textquoteright} community foresees that a new therapeutic era is approaching. In fact, no-chemo options and some molecular targets are on the horizon. This narrative review addresses past, present, and future therapeutic options for HNSCC from a translational point of view.",

keywords = "DNA damage response, Epithelial growth factor receptor, Head and neck squamous cell carcinoma, Immunotherapy",

author = "Morena Fasano and Francesco Perri and Corte, {Carminia Maria Della} and {Di Liello}, Raimondo and Scarpati, {Giuseppina Della Vittoria} and Marco Cascella and Alessandro Ottaiano and Fortunato Ciardiello and Raffaele Solla",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = aug,

doi = "10.3390/biomedicines9081045",

language = "English",

volume = "9",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "8",

}

TY - JOUR

T1 - Translational insights and new therapeutic perspectives in head and neck tumors

AU - Fasano, Morena

AU - Perri, Francesco

AU - Corte, Carminia Maria Della

AU - Di Liello, Raimondo

AU - Scarpati, Giuseppina Della Vittoria

AU - Cascella, Marco

AU - Ottaiano, Alessandro

AU - Ciardiello, Fortunato

AU - Solla, Raffaele

PY - 2021/8

Y1 - 2021/8

N2 - Head and neck squamous cell carcinoma (HNSCC) is characterized by a high mortality rate owing to very few available oncological treatments. For many years, a combination of platinum-based chemotherapy and anti-EGFR antibody cetuximab has represented the only available option for first-line therapy. Recently, immunotherapy has been presented an alternative for positive PD-L1 HNSCC. However, the oncologists’ community foresees that a new therapeutic era is approaching. In fact, no-chemo options and some molecular targets are on the horizon. This narrative review addresses past, present, and future therapeutic options for HNSCC from a translational point of view.

AB - Head and neck squamous cell carcinoma (HNSCC) is characterized by a high mortality rate owing to very few available oncological treatments. For many years, a combination of platinum-based chemotherapy and anti-EGFR antibody cetuximab has represented the only available option for first-line therapy. Recently, immunotherapy has been presented an alternative for positive PD-L1 HNSCC. However, the oncologists’ community foresees that a new therapeutic era is approaching. In fact, no-chemo options and some molecular targets are on the horizon. This narrative review addresses past, present, and future therapeutic options for HNSCC from a translational point of view.

KW - DNA damage response

KW - Epithelial growth factor receptor

KW - Head and neck squamous cell carcinoma

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85113353084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113353084&partnerID=8YFLogxK

U2 - 10.3390/biomedicines9081045

DO - 10.3390/biomedicines9081045

M3 - Review article

AN - SCOPUS:85113353084

VL - 9

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 8

M1 - 1045

ER -

Translational insights and new therapeutic perspectives in head and neck tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this